(c) 2023 PillSync.com

ISOXSUPRINE HYDROCHLORIDE (isoxsuprine hydrochloride 10 mg) Dailymed



IMPRINT: I10     SHAPE: round
    COLOR: white    SCORE: 2

Go PRO for all pill images


Rx Only

Description


Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with the following chemical structure:
C 18H 23NO 3 ∙ HCl p-Hydroxy-α[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol hydrochloride.

Quantitative Ingredient Information: Each tablet taken orally contains 10 or 20 mg Isoxsuprine HCl Pharmacological Class: Peripheral Vasodilator

Indications


Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows:

Possibly Effective

  • For the relief of symptoms associated with cerebrovascular insufficiency.
  • In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease.

Final classification of the less-than-effective indications requires further investigation.

Contraindications


There are no known contraindications to oral use when administered in recommended doses.

Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

Precautions


Pediatric Use


Safety and effectiveness in pediatric patients have not been established.

Adverse Reactions


On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with Isoxsuprine Hydrochloride, a causal relationship can be neither confirmed nor refuted.

Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride have been used to inhibit pre-term labor.

Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received Isoxsuprine Hydrochloride. Pulmonary edema has been reported in mothers treated with beta stimulants. Isoxsuprine Hydrochloride is neither approved nor recommended for use in the treatment of premature labor.

Dosage And Administration


Oral: 10 to 20 mg, three or four times daily.

How Supplied


Isoxsuprine HCl Tablets, USP 10 mg are white, round, biconvex tablets identified as "I10" debossed on one side and bisected on the other.
Bottle of 100 NDC 51293-606-01
Bottle of 1000 NDC 51293-606-10

Isoxsuprine HCl Tablets, USP 20 mg are white, round, biconvex tablets identified as "20" debossed on one side and bisected on the other.
Bottle of 100 NDC 51293-605-01
Bottle of 1000 NDC 51293-605-10

Composition


Isoxsuprine HCl Tablets, 10 mg and 20 mg. These tablets contain the following Inactive Ingredients: Corn Starch, Lactose Monohydrate, Magnesium Stearate (Vegetable), Microcrystalline Cellulose.


Manufactured By: ECI Pharmaceuticals, LLC Fort Lauderdale, FL 33309

Iss. 04/12

Principal Display Panel- 10 Mg Bottle Label


ECI Pharmaceuticals

NDC 51293-606-01

Isoxsuprine Hydrochloride Tablets, USP

10 mg

Rx only

100 Tablets

Principal Display Panel- 20 Mg Bottle Label


ECI Pharmaceuticals

NDC 51293-605-01

Isoxsuprine Hydrochloride Tablets, USP

20 mg

Rx only

100 Tablets

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site